254 related articles for article (PubMed ID: 3923887)
21. Studies on the pathophysiology and treatment of von Willebrand's disease. V. Properties of factor VIII after DDAVP infusion in variant von Willebrand's disease.
Takahashi H
Thromb Res; 1981 Feb 15-Mar 1; 21(4-5):357-65. PubMed ID: 6791293
[No Abstract] [Full Text] [Related]
22. Plasma platelet-activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand's disease.
Kavakli K; Polat A; Hüseyinof A; Nisli G; Aydinok Y
Thromb Haemost; 1999 Apr; 81(4):665-6. PubMed ID: 10235463
[No Abstract] [Full Text] [Related]
23. Treatment of hemophilia A and von Willebrand's disease patients with an intranasal dripping of DDAVP.
Kobayashi I
Thromb Res; 1979; 16(5-6):775-9. PubMed ID: 316584
[No Abstract] [Full Text] [Related]
24. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
Mannucci PM; Canciani MT; Rota L; Donovan BS
Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
[TBL] [Abstract][Full Text] [Related]
25. Estrogens and surgery in women with von Willebrand's disease.
Alperin JB
Am J Med; 1982 Sep; 73(3):367-71. PubMed ID: 6981997
[TBL] [Abstract][Full Text] [Related]
26. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
[TBL] [Abstract][Full Text] [Related]
27. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.
Castaman G; Tosetto A; Rodeghiero F
Haematologica; 2010 Jun; 95(6):963-9. PubMed ID: 19951969
[TBL] [Abstract][Full Text] [Related]
28. [Hyponatremia during therapy of von Willebrand's disease. A life threatening complication after desmopressin (Minitrin) infusion].
Brinch LJ; Jacobsen MB
Tidsskr Nor Laegeforen; 1992 Nov; 112(29):3670-1. PubMed ID: 1471128
[TBL] [Abstract][Full Text] [Related]
29. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
Rodeghiero F; Castaman G; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
[TBL] [Abstract][Full Text] [Related]
30. [Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia A and von Willebrand's disease].
Takase T; Nishino M; Yasui M; Shima M; Yoshikawa N; Fukui H
Nihon Ketsueki Gakkai Zasshi; 1985 Nov; 48(7):1571-8. PubMed ID: 3937410
[No Abstract] [Full Text] [Related]
31. Desmopressin acetate (DDAVP). Good news.
Kasper CK
JAMA; 1984 May; 251(19):2564-5. PubMed ID: 6609247
[No Abstract] [Full Text] [Related]
32. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery.
Kentro TB; Lottenberg R; Kitchens CS
Am J Hematol; 1987 Feb; 24(2):215-9. PubMed ID: 3101493
[TBL] [Abstract][Full Text] [Related]
34. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
Castaman G; Rodeghiero F
Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
[No Abstract] [Full Text] [Related]
35. Desmopressin for hemophilia and other coagulation disorders.
Med Lett Drugs Ther; 1984 Aug; 26(669):82. PubMed ID: 6332266
[No Abstract] [Full Text] [Related]
36. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.
Rodeghiero F; Castaman G; Di Bona E; Ruggeri M
Blood; 1989 Nov; 74(6):1997-2000. PubMed ID: 2804344
[TBL] [Abstract][Full Text] [Related]
37. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors.
Lethagen S; Ragnarson Tennvall G
Ann Hematol; 1993 May; 66(5):257-60. PubMed ID: 8507721
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of hemophilia A and von Willebrand's disease with 1-deamino-8-D-arginine vasopressin (DDAVP). Hemophilia and DDAVP].
Ingerslev J; Christiansen SE; Kristensen T; Wallevik K; Bernvil SS
Ugeskr Laeger; 1985 Nov; 147(45):3592-4. PubMed ID: 3907076
[No Abstract] [Full Text] [Related]
39. [Clinical application of new synthetic vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP): hemostatic control of von Willebrand's disease (author's transl)].
Kobayashi I; Takahashi H; Sanada M; Takahashi K; Hattori A; Ito M; Sakuragawa N; Shibata A; Shinada S; Tsukada T
Rinsho Ketsueki; 1979 Apr; 20(4):364-71. PubMed ID: 312954
[No Abstract] [Full Text] [Related]
40. Desamino-D-arginine vasopressin and bleeding time in von Willebrand's disease.
Isola L; Forster A; Aledort LM
Ann Intern Med; 1984 Nov; 101(5):719-20. PubMed ID: 6435493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
